Categories
Change Password!
Reset Password!
Resmetirom is the first FDA-approved treatment for NASH, showing strong potential to reduce liver fat, improve liver histology, and lower LDL cholesterol, with a favorable safety profile.
Non-alcoholic steatohepatitis (NASH) is a growing global health issue linked to obesity and metabolic disorders. Effective treatment options are currently limited. However, Resmetirom has emerged as a viable therapeutic intervention, particularly for those with moderate to advanced liver fibrosis. The goal was to determine Resmetirom's therapeutic efficacy and safety for noncirrhotic NASH (a severe form of non-alcoholic fatty liver disease [NAFLD]) management.
Investigators conducted a comprehensive literature review across databases like PubMed and Google Scholar focusing on Resmetirom’s pharmacokinetics, pharmacodynamics, clinical efficacy, and safety in NASH care. Resmetirom portrayed remarkable benefits in decreasing liver fat, improving liver histology, and lowering levels of low-density lipoprotein (LDL) cholesterol.
Phase 3 trials indicated improvements in liver fibrosis without deteriorating NAFLD activity score. Generally, mild to moderate adverse events were reported, with gastrointestinal issues such as diarrhea and nausea being the most prevalent.
Resmetirom was safe with no evidence of systemic hypothyroidism or hyperthyroidism. This liver-directed thyroid hormone receptor beta (THR-β) selective agonist marks a major breakthrough in NASH management, especially for those dealing with moderate to advanced fibrosis. It offers a tailored strategy that limits systemic thyroid-linked adverse effects. As the first FDA-authenticated agent for NASH care, it shows promise in alleviating liver fat and improving metabolic and histological parameters. However, additional long-term studies are warranted to fully assess its durability and influence on clinical outcomes.
International Research Journal of Gastroenterology and Hepatology
Resmetirom in the Treatment of Noncirrhotic Non-Alcoholic Steatohepatitis: An In-Depth Review
Chorghe et al.
Comments (0)